Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

Stopped early · Phase 2

Conditions studied: High-risk Diffuse Large B-cell Lymphoma

In brief

The study will estimate the MRD-negative response rate after treatment with blinatumomab in subjects with high-risk DLBCL who are MRD-positive following aHSCT. The clinical hypothesis is that the MRD-negative response rate will be greater than 10%. Achieving an MRD-negative response rate of 30% would be of scientific and clinical interest.

Key facts

Study ID: NCT03298412
Run by: Amgen
People needed: 10
Starts: 2018-05-23
Expected to finish: 2019-09-30
Last updated by the study team: 2020-09-11

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Research Site — Atlanta, Georgia, United States
Research Site — Maywood, Illinois, United States
Research Site — Cleveland, Ohio, United States
Research Site — Dallas, Texas, United States
Research Site — St Leonards, New South Wales, Australia
Research Site — Westmead, New South Wales, Australia
Research Site — Clayton, Victoria, Australia
Research Site — Geelong, Victoria, Australia
Research Site — Charleroi, Belgium
Research Site — Leuven, Belgium
Research Site — Liège, Belgium
Research Site — Créteil, France
Research Site — Lille, France
Research Site — Marseille, France
Research Site — Montpellier, France
Research Site — Paris, France
Research Site — Pessac, France
Research Site — Pierre-Bénite, France
Research Site — Rouen, France
Research Site — Athens, Greece
Research Site — Athens, Greece
Research Site — Thessaloniki, Greece
Research Site — Bergamo, Italy
Research Site — Brescia, Italy
Research Site — Florence, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.